GlassScriptPhysician profile
Asadulla S Mohammed
NPI 1508819350
$91,385.82
in general payments reported to CMS, 2019-2025
48 companies · $3,138 in 2025
The $3,138 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,307 · 2020: $8,304 · 2021: $9,997 · 2022: $16K · 2023: $25K · 2024: $21K · 2025: $3,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $9,535 · Travel and Lodging: $1,364 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,650.00 |
| Food and Beverage | $9,534.70 |
| Travel and Lodging | $1,363.92 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $74,347.01 | 2019-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $2,217.66 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,881.00 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,572.46 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mylan Specialty L.P. | $1,286.48 | 2019-2024 | Yupelri |
| Inspire Medical Systems, INC. | $954.07 | 2020-2024 | Inspire |
| United Therapeutics Corporation | $899.08 | 2019-2025 | Tyvaso, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $761.05 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $743.70 | 2019-2025 | Prolastin-C Liquid |
| Amgen INC. | $690.23 | 2022-2025 | Tezspire, Tavneos |
| Jazz Pharmaceuticals INC. | $592.11 | 2019-2025 | |
| Genzyme Corporation | $558.95 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $537.53 | 2020-2025 | Glassia |
| Insmed, INC. | $405.03 | 2019-2025 | Arikayce |
| Electromed, INC. | $380.87 | 2019-2025 | Smartvest |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asadulla Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.